The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 17, 2024

Filed:

Mar. 11, 2019
Applicant:

Biodesix, Inc., Boulder, CO (US);

Inventors:

Carlos Oliveira, Steamboat Springs, CO (US);

Heinrich Roder, Steamboat Springs, CO (US);

Joanna Roder, Steamboat Springs, CO (US);

Assignee:

Biodesix, Inc., Boulder, CO (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
G16H 20/10 (2018.01); G01N 33/68 (2006.01); G06N 20/00 (2019.01); G16B 40/20 (2019.01); G16H 50/20 (2018.01); H01J 49/00 (2006.01); H01J 49/16 (2006.01); H01J 49/44 (2006.01);
U.S. Cl.
CPC ...
G16H 20/10 (2018.01); G01N 33/6848 (2013.01); G06N 20/00 (2019.01); G16B 40/20 (2019.02); G16H 50/20 (2018.01); H01J 49/0036 (2013.01); H01J 49/164 (2013.01); H01J 49/446 (2013.01);
Abstract

Laboratory test apparatus for conducting a mass spectrometry test on a blood-based sample of a cancer patient includes a classification procedure implemented in a programmed computer that generates a class label. In one form of the test, 'Test 1', if the sample is labelled “Bad” or equivalent the patient is predicted to exhibit primary immune resistance if they are later treated with anti-PD-1 or anti-PD-L1 therapies. In “Test 2” the Bad class label predicts that the patient will have a poor prognosis in response to treatment by either anti-PD-1 or anti-PD-L1 therapies or alternative chemotherapies, such as docetaxel or pemetrexed. “Test 3” identifies patients that are likely to have a poor prognosis in response to treatment by either anti-PD-1 or anti-PD-L1 therapies but have improved outcomes on alternative chemotherapies. A Good class label by either Test 1 or 2 predicts very good outcome on anti-PD-1 or anti-PD-L1 monotherapy.


Find Patent Forward Citations

Loading…